AMLX
NASDAQAmylyx Pharmaceuticals Inc.
Price$37.45-1.02 (-2.64%)
01:30 PM07:45 PM
News · 26 weeks59+1700%
2026-03-012026-08-23
Mix2790d
- Insider11(41%)
- SEC Filings8(30%)
- Earnings5(19%)
- Offering2(7%)
- Other1(4%)
Latest news
25 items- INSIDERChief Financial Officer Frates James M was granted 22,807 shares, increasing direct ownership by 10% to 244,435 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Klee Justin B. was granted 60,039 shares, increasing direct ownership by 2% to 3,643,520 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Legal Officer Mazzariello Gina was granted 21,284 shares, increasing direct ownership by 12% to 200,374 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERCo-Chief Executive Officer Cohen Joshua B was granted 60,039 shares, increasing direct ownership by 2% to 3,643,587 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERChief Medical Officer Bedrosian Camille L was granted 22,807 shares, increasing direct ownership by 9% to 288,092 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- SECSEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.424B5 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECSEC Form 8-K filed by Amylyx Pharmaceuticals Inc.8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being offered by Amylyx. The gross proceeds to Amylyx from this offering are expected to be $500.2 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercis
- SECSEC Form 424B5 filed by Amylyx Pharmaceuticals Inc.424B5 - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being offered by Amylyx. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Amylyx intends to use t
- SECSEC Form 8-K filed by Amylyx Pharmaceuticals Inc.8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECAmylyx Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric HypoglycemiaLUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) LUCIDITY met all secondary endpoints showing consistent, highly statistically significant, and clinically meaningful reductions in Level 2 by self-monitoring of blood glucose (SMBG), Level 2 by CGM, and Level 3 hypoglycemic events Avexitide was generally well-tolerated with a favorable safety profile Amylyx plans to submit an NDA for avexitide with the FDA by year-end; avexitide has Breakthrough Therapy and Orphan Drug Designations by the FDA Company to host investor conference call today, August
- PRAmylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m. ET. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentat
- SECSEC Form 10-Q filed by Amylyx Pharmaceuticals Inc.10-Q - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- SECAmylyx Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
- PRAmylyx Pharmaceuticals Reports Second Quarter 2026 Financial ResultsLast participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August or early September 2026 Cash runway expected to fund operations into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the second quarter ended June 30, 2026. "With the last participant’s final study visit recently completed, we are eagerly anticipating the expected topline data readout of the pivotal Phase 3 LUC
- PRAmylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its second quarter 2026 financial results on Thursday, August 6, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-pr
- INSIDERChief Legal Officer Mazzariello Gina sold $538,868 worth of shares (30,000 units at $17.96) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 179,090 units (SEC Form 4)4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- PRAmylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS (ENCALS) Meeting 2026, held from June 24-26, 2026 in Madrid, Spain. AMX0114 showed no drug-related serious adverse events (SAEs) and no serious neurological adverse events (AEs) in Cohort 1 (lowest dose level 12.5 mg). These safety findings support continued evaluation of AMX0114 at higher dose levels in this multiple ascending dose trial. Biomarker levels, including spectrin breakdown product 145 (SBDP-145), neurofilament light (NfL), and phosphorylated neurofilament heavy
- INSIDERSEC Form 4 filed by Director Firestone Karen4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERSEC Form 4 filed by Director Zeiher Bernhardt G4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERSEC Form 4 filed by Director Milne George M Jr4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERSEC Form 4 filed by Director Quimi Daphne4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
- INSIDERSEC Form 4 filed by Director Fonteyne Paul R.4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)
AMLX FAQ
7 questionsWhat does Amylyx Pharmaceuticals Inc. do?
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Where does AMLX stock trade?
Amylyx Pharmaceuticals Inc. (AMLX) is listed on NASDAQ.What sector and industry is AMLX in?
Amylyx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Amylyx Pharmaceuticals Inc. go public?
Amylyx Pharmaceuticals Inc. (AMLX) completed its IPO in 2022.What are analysts saying about AMLX?
Amylyx Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $2100.00 price target on 2026-03-03. Recent price targets range from $700.00 to $2100.00.What companies are similar to AMLX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AMLX side-by-side with any of them on Quantisnow.How can I track AMLX on Quantisnow?
Quantisnow aggregates Amylyx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMLX to receive live email and push alerts on every new disclosure.